Using BaroStim and CardioMems to improve care for NYHA Class III heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, longitudinal study where each patient serves as their own control before BaroStim implantation. Patients who receive a CardioMems device will undergo three months of guideline-directed medication titration, then receive BaroStim per standard of care and be followed for one year. Follow-up visits will include BaroStim titration and repeated measurements of pulmonary artery diastolic pressure (PADP), 6-minute walk distance, vital signs, NT-proBNP, LVEF, and NYHA class. The protocol aims to use PADP (target ≤18–20 mmHg) from CardioMems as an objective guide to optimize BaroStim therapy and define clinically meaningful improvement as a 10% change in several functional or biomarker measures or any NYHA class improvement.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male or female, ages 18-80 years
4. Diagnosed with NYHA Class III Heart Failure with LVEF\<35%
5. Able to tolerate oral medications for guideline directed medical therapy titration period
6. Have undergone insertion of CardioMems and BaroStim devices per standard of care.
7. It is a standard of care to recommend that females of reproductive potential use highly effective contraception, because of the teratogenic potential of many medications used to treat HFrEF. In addition, withdrawal of GDMT during pregnancy may reverse the positive remodeling and lead to life threatening worsening of heart failure. Women of child-bearing age need to agree to use such a method during study participation and indefinitely after the end of the study.

Exclusion Criteria:

1. Individuals ineligible for either CardioMems or BaroStim devices.
2. NT-proBNP \>1600 mg/dL
3. Indicated for CRT-D device (left bundle branch block)
4. Initial 6-minute walk test distance less than 140 m
5. Left ventricular assist device (LVAD)
6. History of carotid vascular procedure (carotid endarterectomy)
7. Pregnancy or lactation
8. Known allergic reactions to components of the BaroStim or CardioMems insertion or guideline directed medical therapy for heart failure
9. Febrile illness within 30 days of study enrollment
10. Treatment with another investigational drug or other intervention within 1 year
11. Current smoker or tobacco use within 1 year
12. Enrolled in any other CVRx funded study, including investigator-initiated research, registries, or other pre- or post-market studies.
13. Vulnerable individuals as outlined below

Where it's running

• Peconic Bay Medical Center
  Riverhead, New York, United States Recruiting

Study contacts

• Principal investigator: John Kassotis, MD — Northwell Health
• Study coordinator: Shreya Srivastava, MD
• Email: ssrivastava3@northwell.edu
• Phone: 516-881-7067

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Yoga-based cardiac rehabilitation for heart failure with reduced ejection fraction

  This trial tests whether a yoga-based rehabilitation program can help people with heart failure and reduced ejection fraction compared with an educational program.

  Recruiting at 12 sites Centre for Chronic Disease Control, India · Dharwad, Karnataka and 15 other locations · NCT07817589

• SmartSignalHF remote monitoring for people with implanted ICD or CRT‑D and heart failure

  This tests whether SmartSignalHF remote monitoring for people with implanted ICD or CRT‑D and chronic heart failure can reduce deaths and heart failure hospital visits over 12 months compared with standard remote monitoring.

  Recruiting Implicity · Paris · NCT07247032

• Barostim therapy to help heart failure patients stay well

  This study tests whether Barostim System-based baroreflex activation can reduce death and serious heart failure events in adults with moderate heart failure already on guideline-directed therapy.

  Recruiting at 20 sites CVRx, Inc. · Mobile, Alabama and 22 other locations · NCT07232030

• Home palliative care for heart failure patients in rural Appalachia

  This study tests a new home care program for families taking care of loved ones with advanced heart failure in rural Appalachia to see if it improves their quality of life and reduces stress over a year.

  Recruiting West Virginia University · Morgantown, West Virginia · NCT06791850

• Evaluating the Cordella Pulmonary Artery Sensor for Chronic Heart Failure

  This study is testing if a new device that monitors heart pressure at home can help people with chronic heart failure stay out of the hospital and live longer compared to just taking standard medications.

  Recruiting Endotronix, Inc. · Naperville, Illinois · NCT06783335

• Hybrid cardiac rehabilitation for heart failure patients

  This study is testing if a new combined approach to heart rehab that includes exercise, medical support, and education helps people with heart failure feel better and improve their fitness more than just supervised exercise alone.

  Recruiting at 4 sites Universidad de La Frontera · Santiago and 3 other locations · NCT06313684

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.